1-6 of 6
Brad S. Kahl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

Clinical Trials & Observations
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Jeffrey M. Switchenko, Stephen M. Ansell, Nancy L. Bartlett, Kristie A. Blum, Amanda F. Cashen, Carla Casulo, Jonathan W. Friedberg, Patrick B. Johnston, Brad S. Kahl, John P. Leonard, Brian K. Link, Izidore S. Lossos, Peter Martin, Matt J. Maurer, Neha Mehta-Shah, Patrick M. Reagan, Jason R. Westin, Jean L. Koff, Christopher R. Flowers
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2745–2756.
DOI: https://doi.org/10.1182/bloodadvances.2021006504
Published: 2022
Includes: Supplemental data
Journal Articles

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Clinical Trials & Observations
Juan Pablo Alderuccio, Luca Arcaini, Marcus P. Watkins, Anne W. Beaven, Geoffrey Shouse, Narendranath Epperla, Michele Spina, Alexandra Stefanovic, Jose Sandoval-Sus, Pallawi Torka, Ash B. Alpert, Adam J. Olszewski, Seo-Hyun Kim, Brian Hess, Sameh Gaballa, Sabarish Ayyappan, Jorge J. Castillo, Lisa Argnani, Timothy J. Voorhees, Raya Saba, Sayan Mullick Chowdhury, Fernando Vargas, Isildinha M. Reis, Deukwoo Kwon, Jonathan S. Alexander, Wei Zhao, Dali Edwards, Peter Martin, Emanuele Cencini, Manali Kamdar, Brian K. Link, Constantine N. Logothetis, Alex F. Herrera, Jonathan W. Friedberg, Brad S. Kahl, Stefano Luminari, Pier Luigi Zinzani, Izidore S. Lossos
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2035–2044.
DOI: https://doi.org/10.1182/bloodadvances.2021006844
Published: 2022
Journal Articles

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma

Clinical Trials & Observations
Craig A. Portell, Nolan A. Wages, Brad S. Kahl, Lihua E. Budde, Robert W. Chen, Jonathon B. Cohen, Nikole E. Varhegyi, Gina R. Petroni, Michael E. Williams
Journal: Blood Advances
Blood Adv (2022) 6 (5): 1490–1498.
DOI: https://doi.org/10.1182/bloodadvances.2021005357
Published: 2022
Includes: Supplemental data
Journal Articles

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Clinical Trials & Observations
David A. Bond, Jeffrey M. Switchenko, Diego Villa, Kami Maddocks, Michael Churnetski, Alina S. Gerrie, Subir Goyal, Krithika Shanmugasundaram, Oscar Calzada, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Brian T. Hill, Yazeed Sawalha, Peter Martin, Edward Maldonado, Max Gordon, Alexey V. Danilov, Natalie S. Grover, Stephanie Mathews, Madelyn Burkart, Reem Karmali, Nilanjan Ghosh, Steven I. Park, Narendranath Epperla, Talha Badar, Jin Guo, Mehdi Hamadani, Timothy S. Fenske, Mary-Kate Malecek, Brad S. Kahl, Christopher R. Flowers, Kristie A. Blum, Jonathon B. Cohen
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5179–5189.
DOI: https://doi.org/10.1182/bloodadvances.2021004765
Published: 2021
Includes: Supplemental data
Journal Articles

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Bicky Thapa, Paolo F. Caimi, Kirit M. Ardeshna, Melhem Solh, Carmelo Carlo-Stella, Brad S. Kahl, Mehdi Hamadani
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3850–3852.
DOI: https://doi.org/10.1182/bloodadvances.2020002587
Published: 2020
Journal Articles

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael L. Leblanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel J. Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3132–3135.
DOI: https://doi.org/10.1182/bloodadvances.2019000526
Published: 2019